Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Amikacin for COPD Exacerbation Prevention
NCT05213507Phase 3Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amikacin liposome inhalation suspension in chronic obstructive pulmonary disease (COPD), sponsored by Zhongshan Hospital, Fudan University. Status: unknown.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05213507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05213507.